Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has entered into a research collaboration with a major medical institution and renowned researchers to evaluate the efficacy of CPI-613® (devimistat) in combination with chemotherapy agents azacitidine and venetoclax on acute myeloid leukemia (AML) models.
“With generally poor responses to current therapies and a five-year survival rate of just 28%, there are significant gaps in treatments for adult AML patients,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “Fighting AML has long been a goal of ours, and this research explores further options in treating AML, in addition to our current AML trial. Should these experiments show efficacy of devimistat additional AML trials in the upfront setting will be considered. Combined with Rafael’s myelodysplastic syndrome (MDS) trial in development, this will cover the major myeloid malignancies and bring hope to patients suffering from these diseases.”
Rafael also has a Phase 3 clinical trial in AML to evaluate the efficacy of devimistat in combination with chemotherapy agents cytarabine and mitoxantrone. The trial is currently enrolling patients in nearly 50 sites globally.
Rafael’s additional trials in hematological malignancies include a Phase 2 trial in Burkitt’s lymphoma/leukemia, a Phase 1/2 trial in myelodysplastic syndrome, and a Phase 1 trial in T-cell lymphoma.